PARTNERSHIPS
The Right Partners Make the Impossible Happen
At VivaMed BioPharma, partnerships are the driving force behind every breakthrough. We collaborate with leading academic institutions, biotech innovators, and forward-thinking investors to accelerate therapies that matter—because real progress demands more than just potential. It takes alignment, execution, and the right people at the table.
WHY PARTNER WITH US
Your Science Deserves More Than a Hopeful TimelineWhat Makes Us Different to Work With
At VivaMed, we know that promising therapies don’t fail because the science is wrong—they fail because the system is slow, fragmented, and risk-averse.We built a model that eliminates the usual friction points: faster development through AI, deeper regulatory experience, and a team that knows how to take ideas across the finish line.
- AI-powered development across discovery, safety, and IP
- 150+ assets developed or licensed
- 50+ active programs in high-need categories
- 39 regulatory approvals supported
- Academic collaborations across 13+ countries
- Flexible co-development and licensing structures
- A platform built for speed, not bureaucracy
WHAT WE BRING TO THE TABLE
Everything You Need to Accelerate What Matters
Deep Scientific Alignment
We don’t just license compounds—we understand them. Our team includes MDs, PhDs, patent agents, and operators who know how to evaluate, refine, and advance high-potential science.
AI-Accelerated Development
Our proprietary AI systems streamline drug discovery, predict safety profiles, and even generate regulatory documentation—cutting years off the traditional timeline.
Global Execution Infrastructure
From regulatory support to commercialization strategy, we provide the operational power to scale science across borders. Our global partnerships span 30+ institutions in 13 countries.
Capital Formation
VivaMed BioPharma is building a scalable capital formation model anchored in diversified drug asset portfolios and deep strategic partnerships that accelerate development while reducing risk.
STRATEGIC FOCUS, REAL-WORLD IMPACT
We’re not chasing pipelines. We’re fixing what’s broken.
Millions Are Slipping Through the Cracks
Mild Cognitive Impairment and Alzheimer’s affect tens of millions worldwide. Most options are too late—or too weak. We focus on early-stage neuroplasticity therapies designed to slow decline before it becomes irreversible.
Chronic Pain Is a Public Health Crisis
Over 20 million Americans suffer from neuropathic pain. Post-operative opioid use remains a major driver of addiction. We’re developing non-opioid treatments that provide lasting relief—without creating new problems.
The System Fails Dual-Diagnosis Patients
Substance use and trauma are deeply connected, yet rarely treated together. Our therapies address addiction and PTSD in tandem—starting with veterans, frontline workers, and others left behind by traditional care models.
Rare Doesn’t Mean Untreatable
Millions live with rare diseases that have no approved treatments. We accelerate repurposed and orphan-class therapies to bring solutions forward—where time and access are everything.
Still No FDA-Approved ARDS Therapies
Acute Respiratory Distress Syndrome kills up to 40% of those diagnosed. Long-term survivors often face irreversible lung damage. We’re advancing first-in-class biologics to change the standard of care—because supportive care isn’t a strategy.
CONTACT
Let's Connect
Have a question, opportunity, or idea? Whether you’re a researcher, investor, or potential partner—we’d love to hear from you.